Rewiring immunity with in vivo CAR T cell engineering
- Author(s)
- Slaney, CY; Xu, R; Wu, S; Sek, K; Pouton, CW; Dickinson, M; Kershaw, MH; Darcy, PK;
- Journal Title
- Nature Cancer
- Publication Type
- Online publication before print
- Abstract
- Ex vivo engineered chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of certain hematologic malignancies, yet manufacturing complexities and limited patient accessibility constrain its impact. In vivo CAR T cell engineering seeks to overcome these limitations by generating CAR T cells directly within an individual. This Perspective examines the rapidly evolving field of in vivo CAR T cell generation in oncology, outlines principles of lymphocyte targeting, discusses pharmacology and biodistribution and assesses emerging safety issues. We conclude with a translational outlook, highlighting both the opportunities and the outstanding questions that will define the path to clinical implementation.
- Department(s)
- Laboratory Research; Haematology
- Publisher's Version
- https://doi.org/10.1038/s43018-026-01216-0
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2026-09-16 04:38:37
Last Modified: 2026-09-16 04:38:45